Tension between practitioners who believe autologous stem cells should be considered a service and the FDA, which considers some of them biologics, has come to a head in recent months. Laura DeFrancesco investigates.
This is a preview of subscription content, log in via an institution to check access.
References
Lysaght, T. & Campbell, A.V. Cell Stem Cell 9, 393–396 (2011).
Powell, R.J. et al. Mol. Ther. 20, 1280–1286 (2012).
DeFrancesco, L. Nat. Biotechnol. 30, 379 (2012).
Koleva, G. Stem Cells, FDA, and the edge of science: three expert viewpoints. Forbes, 10 February 2012. http://www.forbes.com/sites/gerganakoleva/2012/02/10/stem-cells-and-the-lawsuit-that-may-shape-our-medical-future/
Cuende, N., Rico, L. & Herrera, C. Stem Cells Transl. Med. 1, 403–408 (2012).
Gir, P. et al. Plast. Reconstr. Surg. 129, 1277–1290 (2012).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Adult stem cell therapies walk the line. Nat Biotechnol 30, 739–741 (2012). https://doi.org/10.1038/nbt.2321
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2321
- Springer Nature America, Inc.
This article is cited by
-
Managing the potential and pitfalls during clinical translation of emerging stem cell therapies
Clinical and Translational Medicine (2014)
-
The global industry for unproven stem cell interventions and stem cell tourism
Tissue Engineering and Regenerative Medicine (2014)
-
Fresh from the biotech pipeline—2012
Nature Biotechnology (2013)